CommercialPrior AuthMedium impact
Sunlenca (lenacapavir) (Revised)
Humana·Infectious Disease, Internal Medicine·Commercial
Effective date
Feb 28, 2024
We identified it
Jun 25, 2026
Summary
Humana has revised its prior authorization policy for Sunlenca (lenacapavir), a new HIV-1 capsid inhibitor for heavily treatment-experienced patients with multidrug-resistant HIV infection. The policy requires prior authorization and establishes four strict clinical criteria for coverage, including age ≥18, documented multidrug resistance across three antiretroviral drug classes, use of optimized background regimen, and viral load ≥400 copies/mL. This is a recently updated policy (revised February 28, 2024) affecting commercial plans, and billing teams must implement prior authorization workflows immediately.
Action Required
Before February 28, 2024: Billing and clinical teams must implement prior authorization requirements for Sunlenca (lenacapavir) in all commercial plan submissions. (1) Update billing system to flag all Sunlenca claims for prior authorization. (2) Create pre-authorization checklist requiring documentation of: member age ≥18, HIV-1 diagnosis with resistance/intolerance/contraindication to ≥2 agents in ≥3 of these classes (NRTI, NNRTI, PI, INSTI), evidence of optimized background regimen, and HIV-1 RNA viral load ≥400 copies/mL. (3) Train providers and front desk staff to collect required clinical documentation before submitting claims. (4) Route all Sunlenca requests to clinical review team. (5) Monitor for drug-drug interactions (contraindicated with strong CYP3A inducers). (6) Note: If therapy is discontinued, alternative antiretroviral regimen must be initiated no later than 28 weeks after final injection to prevent resistance. Claims submitted without prior authorization or incomplete clinical documentation will be denied. Refer to Humana's PAL system at www.humana.com/PAL for medical billing codes. Verify current policy version at http://apps.humana.com/tad/tad_new/home.aspx before processing claims.